NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

David Grayzel, MD

David is a Partner at Atlas Venture and focuses on investments in novel therapeutics, often those that are near to first in human clinical testing. In the last ten years, David has co-founded and served as chief executive officer of numerous companies